KENNEDY CAPITAL MANAGEMENT LLC

Position in EDIT — Editas Medicine, Inc.

CIK 884589 ST LOUIS, MO

Position in EDIT

as of Mar 31, 2026 · filed May 13, 2026 Compact

Position Value

$2,599,568

+$1,447,181 QoQ

Shares Held

1,052,457

+87.2% QoQ

Ownership

1.07%

of shares outstanding

% of Portfolio

0.06%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2024

9 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

KENNEDY CAPITAL MANAGEMENT LLC holds $354,986,312 across 62 Biotechnology names. EDIT ranks #43 (0.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	HALO	Halozyme Therapeutics, Inc.	484,580	$31,318,405
2	CPRX	Catalyst Pharmaceuticals, Inc.	1,199,598	$29,702,046
3	PTGX	Protagonist Therapeutics, Inc	137,099	$14,450,234
4	COGT	Cogent Biosciences, Inc.	360,490	$13,875,260
5	NAMS	NewAmsterdam Pharma Co N.V.	408,492	$13,075,828
6	CORT	Corcept Therapeutics Inc	304,615	$12,279,030
7	CLDX	Celldex Therapeutics, Inc.	352,302	$11,175,019
8	APGE	Apogee Therapeutics, Inc.	122,669	$10,325,049

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$2,599,568	1,052,457	+87.2%	Shares	Sole	2026-05-13
2025-12-31	$1,152,387	562,140	-0.6%	Shares	Sole	2026-02-13
2025-09-30	$1,962,774	565,641	-0.3%	Shares	Sole	2025-11-13
2025-06-30	$1,248,761	567,619	+7.8%	Shares	Sole	2025-08-13
2025-03-31	$611,018	526,740	-0.4%	Shares	Sole	2025-05-13
2024-12-31	$671,621	528,836	-2.1%	Shares	Sole	2025-02-13
2024-09-30	$1,841,860	540,135	+307.2%	Shares	Sole	2024-11-14
2024-06-30	$619,466	132,648	-0.4%	Shares	Sole	2024-08-14
2024-03-31	$988,447	133,214	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.